Navigation Links
The Convergent Procedure for the Treatment of Chronic Atrial Fibrillation Highlighted at EACTS Annual Meeting in Geneva
Date:9/13/2010

MORRISVILLE, N.C., Sept. 13 /PRNewswire/ -- The Convergent Procedure, a novel approach to treat atrial fibrillation (AF), enabled by epicardial ablation products from nContact Surgical, Inc. (nContact), was highlighted at the Techno-College Atrial Fibrillation Session of the EACTS (European Association for Cardio-Thoracic Surgery) Annual Meeting in Geneva, Switzerland. More than 1,000 medical professionals attended the 2010 Techno-College Programme to receive an update on the latest technical advancements in cardiothoracic surgery.

The Convergent Procedure is the first multidisciplinary, closed chest treatment for all types of AF.  During the combined epicardial-endocardial ablation procedure, a cardiac surgeon and an electrophysiologist (EP) work as a team to create a comprehensive bi-atrial lesion pattern, without chest incisions or ports. The surgeon utilizes the nContact coagulation device during epicardial ablation to create continuous, linear lesions on a beating heart. The EP then performs endocardial ablation to complete the pattern and utilizes mapping and diagnostics to ensure lesion completeness and that procedure endpoints are achieved.  

Professor Borut Gersak, Head of Cardiovascular Surgery at the University Medical Center, Ljubljana, Slovenia, presented the Convergent Procedure technique and long-term outcomes of 53 patients at six months and 39 patients at twelve months.  Data from the study confirmed over 90% of patients returned to sinus rhythm at six and twelve months post-procedure.  

Commenting on the positive patient data and advantages of the Convergent Procedure, Professor Gersak stated, "The Convergent Procedure merges the best techniques of two cardiac disciplines into a single, complete epicardial-endocardial approach that offers a new treatment opportunity for persistent and longstanding persistent AF patients."

Professor Gerhard Wimmer-Greinecker, Chief of Cardiac Surgery at the Heart and Vascular Center in Bad Bevensen, Germany, who moderated the session and has performed the Convergent Procedure, commented, "The combined epicardial-endocardial procedure potentially enhances the ability to treat new AF patients, decreases total procedure times, reduces physician skills required, and potentially improves outcomes."

About nContact Surgical, Inc.nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF).  The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, continuous, bi-atrial lesions on the epicardium of a beating heart.

To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States.  nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures.  The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.Media ContactsnContact Surgical, Inc. Edgar Rey

1001 Aviation Parkway, Ste 400nContact Surgical

Morrisville, NC  27560T (404) 285-0466

T (919) 466-9810 erey@ncontactsurgical.com

F (919) 466-9811Kimberly Muscara/Jason RandoThe Ruth GroupT (646) 536-7011/7025kmuscara@theruthgroup.com
'/>"/>

SOURCE nContact Surgical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Procedures Consult Mobile From Elsevier Enables Clinicians to View Top Medical Procedures From Mobile Devices
2. Dr. Suresh Koneru Introduces Zeltiq Non-Invasive Procedure For Fat Reduction
3. Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures
4. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
5. Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit
6. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
9. VerteLoc™ Tops 500 Surgical Procedures, VGI Announces VerteLX™ and Seeks Potential Investors for Growth
10. DHS Begins Test of Biometric Exit Procedures at Two U.S. Airports
11. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... LEAWOOD, Kan. , Feb. 22, 2017  Aratana Therapeutics, ... licensing, development and commercialization of innovative biopharmaceutical products for companion ... 14, 2017 at 8:30 a.m. ET to discuss financial results ... 2016. Interested participants and investors may access ... dial-in: ...
(Date:2/22/2017)... Fort Washington, PA (PRWEB) , ... ... ... The Omnia-Prova Education Collaborative (TOPEC), the leading medical education provider of ... Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME). ...
(Date:2/22/2017)... , Feb. 22, 2017 Origin (Origin Agritech, LLC, a ... and seed provider, and Arcadia (Arcadia Biosciences, ... develops and commercializes agricultural productivity traits and nutritional products, today announced ... biotechnology product developed in China to ... trials. ...
(Date:2/22/2017)... SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., ... UTHR ) today announced its financial results ... 2016. "Our annual 2016 financial results ... billion and earnings exceeded $700 million," said Martine ... Officer. "These financial results strengthen our ability to ...
Breaking Biology Technology:
(Date:2/2/2017)... Fla. , Feb. 2, 2017   ... a clinical-stage immuno-oncology company specializing in the development ... for the treatment of cancer and metastatic disease, ... scale-up and GMP manufacturing of a second clinical ... vaccine targeting folate receptor alpha. The manufactured vaccine ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
Breaking Biology News(10 mins):